Smartphone app uses cough sounds to diagnose respiratory disease

ResApp Health Limited, a digital health company producing smartphone applications for the diagnosis and management of respiratory disease, has begun enrolling participants in a study evaluating the feasibility of an app in the diagnosis of pediatric respiratory disease from cough sounds.

SMARTCOUGH-C-2, a multi-site and double-blind study, enrolled 1,667 patient ages 29 days to 12 years who had come into one of three site presenting symptoms of respiratory diseases. The app used for evaluation is based on machine learning algorithms and uses cough sounds to diagnose and rate the severity of respiratory conditions.

The aim of the study is to present a positive and negative agreement to clinical diagnosis of  pneumonia, lower respiratory tract disease, viral lower respiratory tract infection, bronchiolitis, asthma/reactive airways disease, upper respiratory tract disease and croup.

“We are excited to begin the study and take this important next step towards the commercialization of ResAppDx in the United States,” said Tony Keating, CEO and managing director of ResApp. “The refined study protocol, developed in close collaboration with the principal investigators at the recruiting sites, includes major improvements over our previous study in the United States and we look forward to obtaining results which are a true representation of ResAppDx’s performance in mid-2018.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.